Exchange
Nasdaq Stockholm
Every company in the roster listed on Nasdaq Stockholm.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
7 of 7 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Swedish Orphan Biovitrum AB (publ)SOBI · Nasdaq Stockholm | 2 assets: 1 approved, 1 Ph 3 | PegcetacoplanPhase 3 · Chronic Kidney Disease | 25 Jun 2027Pegcetacoplan · Phase 2 |
 BioInvent International ABBINV · Nasdaq Stockholm | 1 asset: 1 Ph 2 | BI-1910Phase 1/2 · Non-Small Cell Lung Cancer | 14 Jul 2027BI-1910 · Phase 1/2 |
 Cantargia ABCANTA · Nasdaq Stockholm | 1 asset: 1 Ph 2 | CAN04Phase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record |
 Hansa BiopharmaHNSA · Nasdaq Stockholm | 1 asset: 1 Ph 3 | ImlifidasePhase 3 · Chronic Kidney DiseaseWeak signal | 28 Feb 2027Imlifidase · Phase 2 |
 Medivir ABMVIR · Nasdaq Stockholm | 1 asset: 1 Ph 2 | BirinapantPhase 2 · Ovarian Cancer | None on record |
 Oncopeptides AB (publ)ONCO · Nasdaq Stockholm | 1 asset: 1 approved | Approved assets only | None on record |
 SanionaSANION · Nasdaq Stockholm | 1 asset: 1 Ph 2 | TesofensinePhase 2 · ObesityReliable signal | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).